Hairy Cell Leukemia-Pipeline Review, H1 2017

Hairy Cell Leukemia-Pipeline Review, H1 2017


  • Products Id :- GMDHC9268IDB
  • |
  • Pages: 89
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hairy Cell Leukemia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia-Pipeline Review, H1 2017, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 2, 1, 3 and 1 respectively.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).

The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hairy Cell Leukemia-Overview

Hairy Cell Leukemia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hairy Cell Leukemia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hairy Cell Leukemia-Companies Involved in Therapeutics Development

AbbVie Inc

ARA Healthcare Pvt Ltd

Astellas Pharma Inc

Cellectis SA

F. Hoffmann-La Roche Ltd

Incyte Corp

Juno Therapeutics Inc

MedImmune LLC

Novartis AG

Hairy Cell Leukemia-Drug Profiles

AGS-67E-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARABS-4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dabrafenib mesylate + trametinib dimethyl sulfoxide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dezapelisib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibrutinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-50465-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-2a-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-2b-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-2b-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itacitinib adipate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

moxetumomab pasudotox-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCART-123-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vadacabtagene leraleucel-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vemurafenib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hairy Cell Leukemia-Dormant Projects

Hairy Cell Leukemia-Discontinued Products

Hairy Cell Leukemia-Product Development Milestones

Featured News & Press Releases

Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours

May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Hairy Cell Leukemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Hairy Cell Leukemia, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hairy Cell Leukemia-Pipeline by AbbVie Inc, H1 2017

Hairy Cell Leukemia-Pipeline by ARA Healthcare Pvt Ltd, H1 2017

Hairy Cell Leukemia-Pipeline by Astellas Pharma Inc, H1 2017

Hairy Cell Leukemia-Pipeline by Cellectis SA, H1 2017

Hairy Cell Leukemia-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Hairy Cell Leukemia-Pipeline by Incyte Corp, H1 2017

Hairy Cell Leukemia-Pipeline by Juno Therapeutics Inc, H1 2017

Hairy Cell Leukemia-Pipeline by MedImmune LLC, H1 2017

Hairy Cell Leukemia-Pipeline by Novartis AG, H1 2017

Hairy Cell Leukemia-Dormant Projects, H1 2017

Hairy Cell Leukemia-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc, ARA Healthcare Pvt Ltd, Astellas Pharma Inc, Cellectis SA, F. Hoffmann-La Roche Ltd, Incyte Corp, Juno Therapeutics Inc, MedImmune LLC, Novartis AG

Hairy Cell Leukemia Therapeutic Products under Development, Key Players in Hairy Cell Leukemia Therapeutics, Hairy Cell Leukemia Pipeline Overview, Hairy Cell Leukemia Pipeline, Hairy Cell Leukemia Pipeline Assessment

select a license
Single User License
USD 2000 INR 143840
Site License
USD 4000 INR 287680
Corporate User License
USD 6000 INR 431520

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com